🇬🇧 English 🇷🇴 Română 🇪🇸 Español soon 🇫🇷 Français soon 🇩🇪 Deutsch soon
Log in Register
e

Johnson & Johnson (JNJ.US) - analysis, score and valuation

Investește acum AD

Is it worth investing?

Johnson & Johnson is a remarkable business, at a price to match.

$258.66 +59.18% over 12 months Last updated: iun. 10, 2026

Johnson & Johnson (JNJ) is a company in the Drug Manufacturers - General industry, listed on NYSE, with a market capitalisation of 623 billion USD. The stock trades at 258.66 USD, close to its 52-week high.

Against trailing twelve-month earnings, the price asks 27.3 times profit, versus 19.2 times for the industry median. Return on equity stands at 27.5%, against an industry median of 21.9%. Revenue has grown 2.7% a year over the past five years.

Over the past twelve months the stock returned +59.2%, against +24.8% for SPY over the same period. The analysis below covers valuation, profitability, growth, the balance sheet and price behaviour, with data updated daily.

Key data

Price and Trading

  • OpenThe price at which Johnson & Johnson shares first traded in the latest session.
  • CloseThe price of the last Johnson & Johnson trade in the session that closed.
  • Day rangeThe lowest and highest price Johnson & Johnson shares reached in that session.
  • VolumeHow many Johnson & Johnson shares changed hands in the latest session.
  • 52-week rangeThe lowest and highest price of Johnson & Johnson shares over the past year.
  • Position in the 52-week rangeWhere the current price of Johnson & Johnson shares sits between the low and the high of the past year. 100% means right at the high.
  • 50-day averageThe average price of Johnson & Johnson shares over the last 50 sessions. Shows the short-term trend.
  • 200-day averageThe average price of Johnson & Johnson shares over the last 200 sessions. Shows the long-term trend.
  • Market capThe market value of all Johnson & Johnson shares combined.

Some values update after the trading session opens, others are recalculated after it closes.

Earnings and Valuation

  • Earnings per shareHow much net profit belongs to a single Johnson & Johnson share over the last twelve months.
  • Estimated earnings, current yearThe earnings per share analysts expect from Johnson & Johnson for the current financial year.
  • Estimated earnings, next yearThe earnings per share expected from Johnson & Johnson for the following financial year.
  • Revenue per shareHow much of the annual sales of Johnson & Johnson belongs to a single share.
  • Book value per shareHow much Johnson & Johnson equity belongs to one share, once debt is subtracted from assets.
  • Revenue, last 12 monthsTotal Johnson & Johnson sales across the last four reported quarters.
  • Price / earningsHow many years of current profit a Johnson & Johnson share costs at today price.
  • Forward price / earningsThe same ratio, but against the profit Johnson & Johnson is expected to make next year.
  • PEGThe price/earnings ratio of Johnson & Johnson divided by its growth rate. Below 1 is considered cheap relative to how fast it grows.
  • Enterprise value / EBITDAThe price of the whole Johnson & Johnson business, debt included, against operating profit before depreciation.

Some values update after the trading session opens, others are recalculated after it closes.

Return and Risk

Low risk · 87
  • Net marginHow much net profit Johnson & Johnson keeps out of every unit of sales.
  • Return on equityHow much net profit Johnson & Johnson produces from shareholder money.
  • Dividend yieldHow much Johnson & Johnson pays out in dividends each year, relative to the share price.
  • Dividend per shareThe estimated annual amount received for each Johnson & Johnson share held.
  • Payout ratioWhat share of Johnson & Johnson profit goes back to shareholders as dividends. The rest stays in the company.
  • BetaHow strongly Johnson & Johnson shares move against the market. 1 means the same, above 1 means wider swings.
  • Debt / equityHow much debt Johnson & Johnson carries for every unit of equity.
  • Short interest as % of floatWhat share of freely tradable Johnson & Johnson stock is sold short, as a bet on a decline.
  • Days to cover short positionsHow many normal trading days it would take to close every short position on Johnson & Johnson.

Some values update after the trading session opens, others are recalculated after it closes.

Indicators for Johnson & Johnson (JNJ) stock

How good the business is, how expensive the price is, and what the chart is doing for JNJ stock. How we calculate the three indicators

Fundamentals

72.6Out of 100

Solid

It stands best on health and risk, 86.6 out of 100; lowest, growth, at 51.0. Against its sector it stands at 70 out of 100, so the two readings confirm each other.

Quality80.2
Growth51.0
Health and risk86.6
Profitability85.3
Free cash flow margin73.9
Low leverage70.6
Gross profitability68.8
Earnings stability65.3
Piotroski F-Score55.6

Valuation

45.4Out of 100

Fair

The business produces 1.6 percentage points a year less than the interest on a government bond. It looks cheapest on earnings against enterprise value (54 out of 100), dearest on price against estimated value (36).

Earnings against market capitalisation: 45.2 out of 100

Earnings yield57.9
P/E (TTM)32.4

Earnings against enterprise value: 54.2 out of 100

EV/EBIT38.2
Acquirer's multiple38.2
Magic Formula yield63.4
EVA yield77.1

Free cash flow against price: 45.9 out of 100

FCF yield45.9

Price against estimated value: 36.4 out of 100

Margin of safety17.2
Price / floor value49.1
EPV vs price43.0

Technical

+75Out of ±100

Strongly positive

Signals: 13 positive and 1 negative, but no clear trend (ADX 14): the price is going nowhere. The heaviest weight comes from the “price against the moving averages” family; the “volume and money flow” family points the other way.

Price against the moving averages: +1.00

Price vs MA200+13.6% from the average
Price vs MA50+3.0% from the average
MA50 vs MA200Short average above the long one

MACD: +1.00

MACD histogram+1.57
MACD line vs 0+1.52

Position in the recent range: +1.00

RSI 1464.8
CCI 20187
Bollinger %B1.01

Long-term momentum: +1.00

Aroon oscillator+56
Coppock+7.9
12-month momentum+53% a year, +47% above the rate

Volume and money flow: -0.50

Money flow CMF-0.045
OBV volume, 50dSlope -0.173

Breakouts and reversals: +1.00

Parabolic SARBelow price, rising
Donchian channelBreak above the 20-day high

Johnson & Johnson (JNJ) stock: arguments for and against

What supports and what weakens the investment case for JNJ stock

Pro18 arguments
  • Out of every 100 units Johnson & Johnson (JNJ) sells, 21.8% is left as profit.After all costs, taxes and interest, 21.8% of sales remains. Companies in the Healthcare sector retain 8.2%.
  • Shareholders' money at Johnson & Johnson earns 27.5% a year.For every unit of capital put in by shareholders, the company makes 27.5% of profit in a year. Companies in the Healthcare sector produce 10.5%.
  • The company bought back shares worth 1.5% of its own value in a year.Buybacks cut the number of shares outstanding, so each remaining share ends up owning a larger slice of the same business.
  • Earnings per share grew 14.9% a year, five years running.The profit attached to each share rose 14.9% in each of the past five years, so the growth reached shareholders too. Companies in the Healthcare sector grew 6.7% a year on average.
  • The balance sheet shows no sign of financial stress.An Altman score of 7.92 sits comfortably above the 2.60 threshold, below which the risk zone would begin.
  • The 50-day price average sits above the 200-day.The price sits 13.6% above its 200-day average. Many investors watch this pattern as a sign of an upward trend.
  • The dividend takes 59.5% of profit, leaving room to grow.For every 100 units of profit, 59.5% goes to shareholders and the rest stays in the business. Companies in the Healthcare sector pay out 33.2%.
  • Money put back into the business earns more than it costs.Every unit reinvested brings 21.3% a year while funding costs 6.0%. As long as the gap stays positive, growth adds value.
  • Short-selling pressure is minimal.Only 1.0% of the freely traded shares are borrowed as a bet on a fall, and buying them back would take 2.94 trading days.
  • Institutions bought on balance last quarter: 12 funds added, 10 cut back.12 funds added to their position and 10 cut back over the past three months. Together they hold 76.8% of the company.
  • Over the last twelve months, Johnson & Johnson shares beat the SPY index by 34.4 points, returning 59.2%.Comparing against the index shows whether the move came from the company or from the market. One year says nothing about the next, but it says who did the work.
  • Revenue at Johnson & Johnson rose in each of the last four quarters, by 7.9% on average.Every quarter came in above the same quarter a year earlier, so the growth is not a single good period. The comparison is year over year precisely so seasonality cannot flatter it.
  • Gross margin improved by 5.1 points against the same quarter a year earlier.More of every unit of sales is left after the direct cost of the product. This is the first place where pricing power or cost control shows up.
  • Net debt is gone within a year: Johnson & Johnson now holds $4.23B more cash than borrowings.A year ago the borrowings were larger than the cash in the bank; now it is the other way round. A company with no net debt does not depend on lenders to get through a weak year, and it can buy while others are selling.
  • Of the last 8 reports, 7 came in above estimates.One good quarter can be luck, a long run suggests the company knows its own numbers and guides conservatively.
  • Through Bear market 2022 it lost 12.7%, less than 98% of comparable companies.How a share fell in a past crisis does not predict the next one, but it shows how it behaves when the whole market sells at once.
  • It scores 87 out of 100 in the stress tests, and in the harshest scenario, Recesiune severă, it would lose 13.8%.The scenarios start from historical shocks and are applied to the company as it stands today. They are exercises rather than forecasts, but they rank the risk.
  • It passes 19 of 30 profile checks, that is 62%.The checks come from different investing styles, from value to growth and quality. Passing many of them means the share fits more than one kind of portfolio.
Against7 arguments
  • Revenue grew 2.7% a year over the past five years.Sales grew 2.7% a year over the past five years. In pharma the pace breaks when patents expire, so a weak year may mean a drug out of protection rather than a declining business. Companies in the Healthcare sector grew 9.2% a year.
  • Johnson & Johnson (JNJ) shares trade at 29.6 times annual earnings, well above the sector.For every unit of annual profit, a buyer pays 29.6. Companies in the Healthcare sector ask 19.5.
  • Free cash is 2.9% of the share price, below the sector.After expenses and investment, what is left equals 2.9% of the share price. Companies in the Healthcare sector generate 4.8%, so the same money invested buys less free cash here.
  • The dividend yields 2.0% a year, below the sector.The dividend yields 2.0% a year on the share price, so anyone looking for regular income will find more elsewhere. Companies in the Healthcare sector pay 5.3%.
  • Johnson & Johnson shares come with debt that would take 1.52 years of earnings to clear.At the current rate, paying it off in full would take 1.52 years. Companies in the Healthcare sector clear it in 1.5 years.
  • Management sold a net $7.36M over the past year.2 separate sellers, with no purchases to offset them. Sales can have personal reasons, but no one in management was buying.
  • The models find no durable competitive advantage.Without an advantage that lasts, earnings depend on how well the company is run each year rather than on its position in the market.

Verdict

The Johnson & Johnson score from 0 to 100, built from over 400 financial indicators. Not investment advice.

Neutral
ExpensiveSolidQuality
  • In Healthcare, Johnson & Johnson is above the sector average on stability, quality and momentum.
  • neutral verdicts returned a median of +12.2% over one year, across 63,296 assessments.

At Johnson & Johnson, earnings per share have grown 18% a year for three years.
But the price asks 2.4 times the estimated value.

Return on capital exceeds the cost of that capital. Net profit has grown 13% a year over five years. Operating profit covers interest 41 times over.

Analysis produced automatically by einvestitii.ro, on data as of oct. 1, 2026. It is not investment advice. Who produces it, what it rests on and what conflicts of interest exist: see the full disclosure.

What it is really worth

Value & Valuation

The market price is what buyers are asking today. Here we work out what the share should cost based on the company’s own figures: using the valuation models professional investors rely on, the growth the current price assumes, and the target set by the analysts who follow the company.

what analysts think

What the analysts covering Johnson & Johnson think, and where they see the price 12 months out. These are their estimates, not ours.

Analyst consensus

What the 24 analysts covering Johnson & Johnson think

Buy

average 3.75 out of 5, from 24 analysts

Strong sellStrong buy
  • Strong sell00%
  • Sell00%
  • Hold1354%
  • Buy417%
  • Strong buy729%

The analyst consensus is more optimistic than our score, by 14 points on the same 0 to 100 scale.

Analyst estimates, third-party source. These are not our verdict.

Price target

Where analysts see Johnson & Johnson shares 12 months out

$252.96

+6.07% against today price

52-week low $145.3952-week high $250.24
  • today$258.66
  • target$252.96

The target falls outside the 52-week range for Johnson & Johnson; the marker is capped at the end.

Rise from the low of the past year+77.91%
Fall from the high of the past year+3.36%
  • Price today$258.66
  • Revisions, last 30 days18 ↑2 ↓
  • Expected earnings growth+9.79%
  • Analysts covering24

Analyst estimates, third-party source.

Transparency · MAR

fair value

Overvalued

What Johnson & Johnson shares should cost, according to the valuation models of the best-known investors in history.

Estimated fair value

The average of the Graham, Buffett, Lynch models, and others.

$105.95−59.0% versus price

the price is 2.44 times the estimate from 5 models

×1×2
fair range $92.73 - $231.82price today $258.66

Logarithmic scale; the marks are multiples of the fair value.

Price versus estimate 2.44×Confidence in the estimate: HighSpread across models 34%Median of 5 models

These are estimates, not price targets: every model starts from assumptions about the future, and if the assumptions change, so does the number.

The models, one by one

7 methods with a value for Johnson & Johnson. The fair value above is the median across 5 of them, chosen by how well they fit the company. All of them are here, for reference.

Graham Number$81.44−68.5% versus price
Buffett with growth$291.11+12.5% versus price
Buffett without growth$104.02−59.8% versus price
Lynch Fair Price$105.95−59.0% versus price
Earnings Power Value (EPV)$114.75−55.6% versus price
Absolute floor$89.33−65.5% versus price
DCF value$363.50+40.5% versus price

Transparency · MAR

projections

These are not predictions. The model splits the possible outcomes into ranges and reports how often the price landed in each, across similar cases in the past.

computed on 9 august 2026

Where the price could go

The price range Johnson & Johnson shares could fall into, from six months out to five years

6 months

Where the price could go

The price range Johnson & Johnson shares could fall into, from six months out to five years

+2.0%most likely · $243.35
Pessimistic −14%Optimistic +25%
  • Today's price$238.49
  • Median$243.35
Pessimistic scenario$205.48
Optimistic scenario$297.73

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

With what probability

Estimated chances for the next six months

More often up

  • Chance it ends higher than today62%
  • Chance it beats the indexindex +4.8%44%
  • Chance of a gain over 20%16%
  • Chance of a drop over 10%17%
  • Chance of a drop over 20%6%

12 months

Where the price could go

The price range Johnson & Johnson shares could fall into, from six months out to five years

−3.0%most likely · $231.29
Pessimistic −18%Optimistic +4%
  • Today's price$238.49
  • Median$231.29
Pessimistic scenario$196.13
Optimistic scenario$247.92

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

With what probability

Estimated chances for the next six months

No clear tilt

  • Chance it ends higher than today52%
  • Chance it beats the indexindex +9.6%10%
  • Chance of a gain over 20%7%
  • Chance of a drop over 10%19%
  • Chance of a drop over 20%9%

3 years

Where the price could go

The price range Johnson & Johnson shares could fall into, from six months out to five years

+10.3%most likely · $263.06
Pessimistic +11%Optimistic +10%
  • Today's price$238.49
  • Median$263.06
Pessimistic scenario$263.76
Optimistic scenario$261.66

Expected growth over 3 years, per year: +3.3% per year, between +3% and +3%.

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

Where the return comes from

Today's price embeds a high expectation. The model assumes investors will, over time, pay less for the same profit, and that difference is subtracted from the annual growth.

  • earnings growth+4.8%
  • the dividend+3.5%
  • multiple re-rating−5.0%

5 years

Where the price could go

The price range Johnson & Johnson shares could fall into, from six months out to five years

+18.0%most likely · $281.33
Pessimistic +18%Optimistic +25%
  • Today's price$238.49
  • Median$281.33
Pessimistic scenario$282.08
Optimistic scenario$297.62

Expected growth over 5 years, per year: +3.4% per year, between +3% and +5%.

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

Where the return comes from

Today's price embeds a high expectation. The model assumes investors will, over time, pay less for the same profit, and that difference is subtracted from the annual growth.

  • earnings growth+4.9%
  • the dividend+3.5%
  • multiple re-rating−5.0%

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

Transparency · MAR

How the business is actually doing

The Business & Its Results

Fundamental analysis of Johnson & Johnson (JNJ) stock: profitability, growth rate and capital efficiency, measured on reported figures. The fundamental score is 48.8 out of 100, held up by quality and pulled down by value.

48.8 · average

value17.5/100
quality80.2/100
growth51.0/100
dividends46.3/100

the business and its results

Solid results

How profitable is it?

82 · strong

Capital invested in Johnson & Johnson produces 21.32% a year, and shareholders' equity 27.50%. Above what most companies in the sector manage.

  • Return on invested capitalProfit generated from all capital employed — equity and debt alike. Above the cost of capital (WACC) means value is created. Above 15% is very good.
  • Return on equityHow much net profit the company generates from shareholders' money. Above ~15% is very good; consistency matters as much as the level.
  • Return on assetsHow much profit the company draws from the assets it owns. Above ~5% is solid, though it varies widely by industry.
  • Gross profitabilityGross profit against assets — the quality measure proposed by Novy-Marx. High readings point to a durable competitive advantage.
  • Free cash flow marginHow much of sales is left as free cash after investment. Above ~15% is very healthy.
  • Cash operating profitabilityProfitability measured on cash actually collected, not on accounting profit. High readings mean reported profit is backed by real money.
  • ROIC − WACC spreadThe gap between the return on capital and what that capital costs. Positive means invested capital adds value. Negative means it destroys value.
  • Net margin (DuPont breakdown)The margin component of the DuPont breakdown of returns. Higher means the firm keeps more of every unit sold.

How fast does it grow?

58 · solid

Johnson & Johnson revenue grew 2.67% a year over the past five years, and net profit 12.74%.

  • Revenue growth (5-year annual)Average yearly revenue growth over the past five years. Above ~10% is solid growth for a mature company.
  • Earnings per share growth (5-year annual)Average yearly growth in earnings per share. Faster than revenue means expanding margins or buybacks.
  • Free cash flow growth (5-year annual)Average yearly growth in free cash flow. Keeping pace with profit means growth is backed by real money.
  • Net income growth (5-year annual)Average yearly growth in net income. Steady and positive points to a predictable business model.
  • Rule of 40Revenue growth added to the profitability margin. Above 40 means a good balance between growth and profitability.
  • Consecutive years of dividend growthHow many years in a row the dividend per share has grown, without a single break. A long streak shows a company that can afford to raise the payout to shareholders year after year.

Is profit backed by real cash?

40 · weak

The Johnson & Johnson Piotroski score is 5 out of 9. The earnings quality signals are mixed.

  • Piotroski F-score (0–9)Nine financial health checks; each one passed adds a point. 7 or more means improving fundamentals.
  • Beneish M-scoreModel that detects patterns of aggressive accounting. Below −1.78 means no signals of aggressive reporting. A statistical test, not an accusation.
  • Montier C-score (0–6)Six warning signals about the quality of accounting. 0–1 is clean; 4 or above calls for caution.
  • Accruals ratio (Sloan)How much of reported profit is accounting only, rather than cash collected. Low or negative means profit is backed by real money.
  • Stock-based compensation dilutionHow much of shareholders' stake is diluted by shares granted to employees. Below 2% a year is bearable dilution.

How efficiently does it use its money?

56 · solid

Money put into sales comes back to Johnson & Johnson in 101 days.

  • Cash conversion cycleHow many days pass between paying suppliers and collecting from customers. Low or negative means the company funds operations with its partners' money.
  • Cash conversion cycle (5-year average)The five-year average of the conversion cycle — it shows consistency, not just this year. Stable and low means durable operational discipline.
  • Cash conversion rateHow much of accounting profit actually turns into cash. Above 100% means profit is more than covered by real money.
  • ROIC minus WACC spread (5-year average)The same gap between the return on capital and its cost, but computed on the five-year average return rather than the current year. Positive and stable means growth worth financing.

The scores are percentiles against companies in the same sector, not absolute marks. A low score means the sector is doing better, not necessarily that the figures are bad.

financial data

The income statement, balance sheet and cash flows of Johnson & Johnson. Totals and main components are shown by default; the rest open from “all rows”.

revenue$94.19 bn+6.0%201620252016$71.89 bn2017$76.45 bn2018$81.58 bn2019$82.06 bn2020$82.58 bn2021$78.74 bn2022$79.99 bn2023$85.16 bn2024$88.82 bn2025$94.19 bn
operating income$25.60 bn+15.6%201620252016$20.89 bn2017$18.90 bn2018$21.18 bn2019$20.97 bn2020$19.73 bn2021$20.94 bn2022$21.01 bn2023$21.85 bn2024$22.15 bn2025$25.60 bn
net income$26.80 bn+90.6%201620252016$16.54 bn2017$1.30 bn2018$15.30 bn2019$15.12 bn2020$14.71 bn2021$20.88 bn2022$17.94 bn2023$35.15 bn2024$14.07 bn2025$26.80 bn
Income statement, annual, 6 periods
 2025Δ 202420242023202220212020
$94.19 bn100%+6.0%$88.82 bn100%$85.16 bn100%$79.99 bn100%$78.74 bn100%$82.58 bn100%

Everything the company collected from sales, before any expense. At Johnson & Johnson, in 2025: $94.19 bn · Δ +6.0% (2024).

$25.64 bn27.2%−6.7%$27.47 bn30.9%$26.74 bn31.4%$24.60 bn30.7%$23.40 bn29.7%$28.43 bn34.4%

What it cost to produce what was sold: materials, labour, the factory. At Johnson & Johnson, in 2025: $25.64 bn · Δ −6.7% (2024).

$68.56 bn72.8%+11.7%$61.35 bn69.1%$58.41 bn68.6%$55.39 bn69.3%$55.34 bn70.3%$54.16 bn65.6%

What is left from sales after the direct cost of the product, before admin salaries and research. At Johnson & Johnson, in 2025: $68.56 bn · Δ +11.7% (2024).

gross margin72.8%72.8%69.1%69.1%68.6%68.6%69.3%69.3%70.3%70.3%65.6%65.6%
$14.67 bn15.6%−14.9%$17.23 bn19.4%$15.05 bn17.7%$14.14 bn17.7%$14.28 bn18.1%$12.34 bn14.9%

Money put into tomorrow’s products: research, engineering, software. At Johnson & Johnson, in 2025: $14.67 bn · Δ −14.9% (2024).

$23.68 bn25.1%+7.8%$21.97 bn24.7%$21.01 bn24.7%$20.25 bn25.3%$20.12 bn25.5%$22.08 bn26.7%

Sales and admin salaries, marketing, rent, everything that keeps the company running. At Johnson & Johnson, in 2025: $23.68 bn · Δ +7.8% (2024).

of which: selling and marketing—-—-$500.0 m0.6%$2.10 bn2.6%$2.70 bn3.4%$2.10 bn2.5%
$68.60 bn72.8%−22.8%$88.82 bn100%$63.30 bn74.3%$58.98 bn73.7%$57.80 bn73.4%$62.85 bn76.1%

The sum of all costs: cost of product plus operating expenses. At Johnson & Johnson, in 2025: $68.60 bn · Δ −22.8% (2024).

$42.96 bn45.6%−35.6%$66.67 bn75.1%$36.56 bn42.9%$34.38 bn43.0%$34.40 bn43.7%$34.42 bn41.7%

The sum of expenses that do not go directly into the product. At Johnson & Johnson, in 2025: $42.96 bn · Δ −35.6% (2024).

$25.60 bn27.2%+15.6%$22.15 bn24.9%$21.85 bn25.7%$21.01 bn26.3%$20.94 bn26.6%$19.73 bn23.9%

Profit from the core business, before interest and tax. At Johnson & Johnson, in 2025: $25.60 bn · Δ +15.6% (2024).

operating margin27.2%27.2%24.9%24.9%25.7%25.7%26.3%26.3%26.6%26.6%23.9%23.9%
$41.06 bn43.6%+65.7%$24.78 bn27.9%$29.34 bn34.5%$26.61 bn33.3%$26.75 bn34.0%$23.93 bn29.0%

Profit before interest, tax and depreciation. Close to the cash the business produces. At Johnson & Johnson, in 2025: $41.06 bn · Δ +65.7% (2024).

$33.55 bn35.6%+92.4%$17.44 bn19.6%$21.85 bn25.7%$19.64 bn24.5%$19.36 bn24.6%$16.70 bn20.2%

Profit before interest and tax. At Johnson & Johnson, in 2025: $33.55 bn · Δ +92.4% (2024).

Depreciation and amortisation$7.50 bn8.0%+2.2%$7.34 bn8.3%$7.49 bn8.8%$6.97 bn8.7%$7.39 bn9.4%$7.23 bn8.8%
Reconciled depreciation$7.50 bn8.0%+2.2%$7.34 bn8.3%$7.49 bn8.8%$6.97 bn8.7%$7.39 bn9.4%$7.23 bn8.8%
Interest income$1.06 bn1.1%−20.7%$1.33 bn1.5%$1.26 bn1.5%$490.0 m0.6%$53.0 m0.1%$111.0 m0.1%
Interest expense$971.0 m1.0%+28.6%$755.0 m0.9%$1.25 bn1.5%$276.0 m0.3%$183.0 m0.2%$201.0 m0.2%
Net interest income$85.0 m0.1%−85.3%$577.0 m0.6%$489.0 m0.6%$214.0 m0.3%−$130.0 m-0.2%−$90.0 m-0.1%
—-—-—-−$1.38 bn-1.7%−$436.0 m-0.6%−$2.79 bn-3.4%

Gains and losses that do not come from the core business.

$6.99 bn7.4%+216%−$6.05 bn-6.8%−$6.79 bn-8.0%−$1.65 bn-2.1%−$1.77 bn-2.2%−$3.24 bn-3.9%

The balance of all non-operating income and expense. At Johnson & Johnson, in 2025: $6.99 bn · Δ +216% (2024).

−$1.00 bn-1.1%$00.0%$21.83 bn25.6%$1.57 bn2.0%—-$300.0 m0.4%

Gains or losses that do not repeat and do not belong to normal operations. At Johnson & Johnson, in 2025: −$1.00 bn.

$32.58 bn34.6%+95.2%$16.69 bn18.8%$15.06 bn17.7%$19.36 bn24.2%$19.18 bn24.4%$16.50 bn20.0%

Profit left after interest, but before the state takes its share. At Johnson & Johnson, in 2025: $32.58 bn · Δ +95.2% (2024).

$5.78 bn6.1%+120%$2.62 bn3.0%$1.74 bn2.0%$2.99 bn3.7%$1.38 bn1.7%$1.78 bn2.2%

Income tax owed for the period. At Johnson & Johnson, in 2025: $5.78 bn · Δ +120% (2024).

Tax provision$5.78 bn6.1%+120%$2.62 bn3.0%$1.74 bn2.0%$2.99 bn3.7%$1.38 bn1.7%$1.78 bn2.2%
$26.80 bn28.5%+90.6%$14.07 bn15.8%$13.33 bn15.6%$16.37 bn20.5%$17.80 bn22.6%$14.71 bn17.8%

Profit from the businesses the company will still have next year. At Johnson & Johnson, in 2025: $26.80 bn · Δ +90.6% (2024).

$26.80 bn28.5%+90.6%$14.07 bn15.8%$35.15 bn41.3%$17.94 bn22.4%$20.88 bn26.5%$14.71 bn17.8%

The profit left for shareholders after absolutely every expense. At Johnson & Johnson, in 2025: $26.80 bn · Δ +90.6% (2024).

net margin28.5%28.5%15.8%15.8%41.3%41.3%22.4%22.4%26.5%26.5%17.8%17.8%
$26.80 bn28.5%+90.6%$14.07 bn15.8%$35.15 bn41.3%$17.94 bn22.4%$20.88 bn26.5%$14.71 bn17.8%

The share of profit that belongs to ordinary shares. At Johnson & Johnson, in 2025: $26.80 bn · Δ +90.6% (2024).

nonRecurring—-—-—-$1.10 bn1.4%$1.15 bn1.5%$428.0 m0.5%
revenue$24.06 bn+9.9%Q2 24Q1 26Q2 24$22.45 bnQ3 24$22.47 bnQ4 24$22.52 bnQ1 25$21.89 bnQ2 25$23.74 bnQ3 25$23.99 bnQ4 25$24.56 bnQ1 26$24.06 bn
operating income$6.40 bn+1.5%Q2 24Q1 26Q2 24$6.66 bnQ3 24$5.28 bnQ4 24$3.84 bnQ1 25$6.30 bnQ2 25$6.81 bnQ3 25$7.10 bnQ4 25$5.59 bnQ1 26$6.40 bn
net income$5.24 bn−52.4%Q2 24Q1 26Q2 24$4.69 bnQ3 24$2.69 bnQ4 24$3.43 bnQ1 25$11.00 bnQ2 25$5.54 bnQ3 25$5.15 bnQ4 25$5.12 bnQ1 26$5.24 bn
Income statement, quarterly, 6 periods
 Q1 26Δ Q1 25Q4 25Q3 25Q2 25Q1 25Q4 24
$24.06 bn100%+9.9%$24.56 bn100%$23.99 bn100%$23.74 bn100%$21.89 bn100%$22.52 bn100%

Everything the company collected from sales, before any expense. At Johnson & Johnson, in Q1 26: $24.06 bn · Δ +9.9% (Q1 25).

$6.86 bn28.5%−6.8%$7.97 bn32.4%$7.30 bn30.4%$7.63 bn32.1%$7.36 bn33.6%$7.13 bn31.7%

What it cost to produce what was sold: materials, labour, the factory. At Johnson & Johnson, in Q1 26: $6.86 bn · Δ −6.8% (Q1 25).

$17.20 bn71.5%+18.3%$16.60 bn67.6%$16.69 bn69.6%$16.12 bn67.9%$14.54 bn66.4%$15.39 bn68.3%

What is left from sales after the direct cost of the product, before admin salaries and research. At Johnson & Johnson, in Q1 26: $17.20 bn · Δ +18.3% (Q1 25).

gross margin71.5%71.5%67.6%67.6%69.6%69.6%67.9%67.9%66.4%66.4%68.3%68.3%
$3.53 bn14.7%+9.4%$4.25 bn17.3%$3.67 bn15.3%$3.52 bn14.8%$3.23 bn14.7%$5.30 bn23.5%

Money put into tomorrow’s products: research, engineering, software. At Johnson & Johnson, in Q1 26: $3.53 bn · Δ +9.4% (Q1 25).

$6.03 bn25.1%+20.4%$6.95 bn28.3%$5.92 bn24.7%$5.79 bn24.4%$5.01 bn22.9%$6.25 bn27.8%

Sales and admin salaries, marketing, rent, everything that keeps the company running. At Johnson & Johnson, in Q1 26: $6.03 bn · Δ +20.4% (Q1 25).

$17.67 bn73.4%+13.3%$18.97 bn77.2%$16.90 bn70.4%$16.93 bn71.3%$15.59 bn71.2%$18.68 bn82.9%

The sum of all costs: cost of product plus operating expenses. At Johnson & Johnson, in Q1 26: $17.67 bn · Δ +13.3% (Q1 25).

$10.81 bn44.9%+31.2%$11.01 bn44.8%$9.59 bn40.0%$9.31 bn39.2%$8.24 bn37.6%$11.55 bn51.3%

The sum of expenses that do not go directly into the product. At Johnson & Johnson, in Q1 26: $10.81 bn · Δ +31.2% (Q1 25).

$6.40 bn26.6%+1.5%$5.59 bn22.8%$7.10 bn29.6%$6.81 bn28.7%$6.30 bn28.8%$3.84 bn17.1%

Profit from the core business, before interest and tax. At Johnson & Johnson, in Q1 26: $6.40 bn · Δ +1.5% (Q1 25).

operating margin26.6%26.6%22.8%22.8%29.6%29.6%28.7%28.7%28.8%28.8%17.1%17.1%
$6.40 bn26.6%−59.0%$7.19 bn29.3%$9.29 bn38.7%$8.74 bn36.8%$15.61 bn71.3%$5.92 bn26.3%

Profit before interest, tax and depreciation. Close to the cash the business produces. At Johnson & Johnson, in Q1 26: $6.40 bn · Δ −59.0% (Q1 25).

—-$5.18 bn21.1%$7.51 bn31.3%$6.80 bn28.6%$13.84 bn63.2%$4.02 bn17.9%

Profit before interest and tax.

Depreciation and amortisation—-$2.01 bn8.2%$1.78 bn7.4%$1.94 bn8.2%$1.77 bn8.1%$1.90 bn8.4%
Reconciled depreciation$2.00 bn8.3%+13.1%$2.01 bn8.2%$1.78 bn7.4%$1.94 bn8.2%$1.77 bn8.1%$1.90 bn8.4%
Interest income$229.0 m1.0%−31.0%$237.0 m1.0%$227.0 m0.9%$260.0 m1.1%$332.0 m1.5%$281.0 m1.2%
Interest expense$43.0 m0.2%−78.9%$214.0 m0.9%$245.0 m1.0%$308.0 m1.3%$204.0 m0.9%$137.0 m0.6%
Net interest income−$43.0 m-0.2%−134%$23.0 m0.1%−$18.0 m-0.1%−$48.0 m-0.2%$128.0 m0.6%$144.0 m0.6%
−$405.0 m-1.7%−106%−$625.0 m-2.5%$397.0 m1.7%−$319.0 m-1.3%$7.33 bn33.5%$46.0 m0.2%

The balance of all non-operating income and expense. At Johnson & Johnson, in Q1 26: −$405.0 m · Δ −106% (Q1 25).

—-—-—-—-—-$00.0%

Gains or losses that do not repeat and do not belong to normal operations.

$5.99 bn24.9%−56.1%$4.97 bn20.2%$7.49 bn31.2%$6.49 bn27.3%$13.63 bn62.3%$3.89 bn17.3%

Profit left after interest, but before the state takes its share. At Johnson & Johnson, in Q1 26: $5.99 bn · Δ −56.1% (Q1 25).

$755.0 m3.1%−71.3%−$150.0 m-0.6%$2.34 bn9.8%$954.0 m4.0%$2.63 bn12.0%$456.0 m2.0%

Income tax owed for the period. At Johnson & Johnson, in Q1 26: $755.0 m · Δ −71.3% (Q1 25).

Tax provision$755.0 m3.1%−71.3%−$150.0 m-0.6%$2.34 bn9.8%$954.0 m4.0%$2.63 bn12.0%$456.0 m2.0%
$5.24 bn21.8%−52.4%$5.12 bn20.8%$5.15 bn21.5%$5.54 bn23.3%$11.00 bn50.2%$3.43 bn15.2%

Profit from the businesses the company will still have next year. At Johnson & Johnson, in Q1 26: $5.24 bn · Δ −52.4% (Q1 25).

$5.24 bn21.8%−52.4%$5.12 bn20.8%$5.15 bn21.5%$5.54 bn23.3%$11.00 bn50.2%$3.43 bn15.2%

The profit left for shareholders after absolutely every expense. At Johnson & Johnson, in Q1 26: $5.24 bn · Δ −52.4% (Q1 25).

net margin21.8%21.8%20.8%20.8%21.5%21.5%23.3%23.3%50.2%50.2%15.2%15.2%
—-$5.12 bn20.8%$5.15 bn21.5%$5.54 bn23.3%$11.00 bn50.2%$3.43 bn15.2%

The share of profit that belongs to ordinary shares.

total assets$199.21 bn+10.6%201620252016$141.21 bn2017$157.30 bn2018$152.95 bn2019$157.73 bn2020$174.89 bn2021$182.02 bn2022$187.38 bn2023$167.56 bn2024$180.10 bn2025$199.21 bn
total liabilities$117.67 bn+8.3%201620252016$70.79 bn2017$97.14 bn2018$93.20 bn2019$98.26 bn2020$111.62 bn2021$108.00 bn2022$110.57 bn2023$98.78 bn2024$108.61 bn2025$117.67 bn
shareholders equity$81.54 bn+14.1%201620252016$70.42 bn2017$60.16 bn2018$59.75 bn2019$59.47 bn2020$63.28 bn2021$74.02 bn2022$76.80 bn2023$68.77 bn2024$71.49 bn2025$81.54 bn
Balance sheet, annual, 6 periods
 2025Δ 202420242023202220212020
$199.21 bn100%+10.6%$180.10 bn100%$167.56 bn100%$187.38 bn100%$182.02 bn100%$174.89 bn100%

Everything the company owns: factories, inventory, cash, receivables. At Johnson & Johnson, in 2025: $199.21 bn · Δ +10.6% (2024).

$55.62 bn27.9%−0.5%$55.89 bn31.0%$53.50 bn31.9%$55.29 bn29.5%$60.98 bn33.5%$51.24 bn29.3%

What turns into money in less than a year. At Johnson & Johnson, in 2025: $55.62 bn · Δ −0.5% (2024).

Cash$19.71 bn9.9%−18.2%$24.11 bn13.4%$21.86 bn13.0%$12.89 bn6.9%$14.49 bn8.0%$13.99 bn8.0%
Cash and equivalents$5.99 bn3.0%−2.1%$6.12 bn3.4%$4.81 bn2.9%$5.37 bn2.9%$1.90 bn1.0%$2.10 bn1.2%
Short-term investments$393.0 m0.2%−5.8%$417.0 m0.2%$1.07 bn0.6%$9.39 bn5.0%$17.12 bn9.4%$11.20 bn6.4%
Cash and short-term investments$20.10 bn10.1%−18.0%$24.52 bn13.6%$22.93 bn13.7%$22.28 bn11.9%$31.61 bn17.4%$25.19 bn14.4%
Net receivables$17.18 bn8.6%−9.2%$18.93 bn10.5%$14.87 bn8.9%$16.92 bn9.0%$18.98 bn10.4%$13.58 bn7.8%
Inventory$14.19 bn7.1%+14.0%$12.44 bn6.9%$11.18 bn6.7%$10.27 bn5.5%$10.39 bn5.7%$9.34 bn5.3%
Other current assets$4.15 bn2.1%—-$4.51 bn2.7%$5.83 bn3.1%$3.70 bn2.0%$3.13 bn1.8%
$143.59 bn72.1%+15.6%$124.21 bn69.0%$114.06 bn68.1%$132.08 bn70.5%$121.04 bn66.5%$123.66 bn70.7%

What stays in the company for years: buildings, machinery, licences. At Johnson & Johnson, in 2025: $143.59 bn · Δ +15.6% (2024).

Property, plant and equipment$24.47 bn12.3%+13.2%$21.62 bn12.0%$20.90 bn12.5%$19.80 bn10.6%$18.96 bn10.4%$18.77 bn10.7%
PP&E, net$23.17 bn11.6%+12.9%$20.52 bn11.4%$19.90 bn11.9%$17.98 bn9.6%$18.96 bn10.4%$18.77 bn10.7%
$54.36 bn27.3%+11.5%$48.77 bn27.1%$47.78 bn28.5%$49.25 bn26.3%$47.68 bn26.2%$18.77 bn10.7%

The purchase value of buildings and machinery, before accumulated depreciation. That is why it exceeds the net value. At Johnson & Johnson, in 2025: $54.36 bn · Δ +11.5% (2024).

Goodwill$48.77 bn24.5%+10.3%$44.20 bn24.5%$36.56 bn21.8%$36.05 bn19.2%$35.25 bn19.4%$36.39 bn20.8%
Intangible assets$50.40 bn25.3%+34.0%$37.62 bn20.9%$34.18 bn20.4%$38.49 bn20.5%$46.39 bn25.5%$53.40 bn30.5%
Other non-current assets$14.37 bn7.2%+25.9%$11.41 bn6.3%$14.15 bn8.4%$30.62 bn16.3%$10.22 bn5.6%$6.56 bn3.8%
Other assets$8.6 m0.0%−100.0%$20.32 bn11.3%$17.96 bn10.7%$17.05 bn9.1%$17.16 bn9.4%$3.90 bn2.2%
$117.67 bn59.1%+8.3%$108.61 bn60.3%$98.78 bn59.0%$110.57 bn59.0%$108.00 bn59.3%$111.62 bn63.8%

Everything the company owes, to banks and suppliers alike. At Johnson & Johnson, in 2025: $117.67 bn · Δ +8.3% (2024).

$54.13 bn27.2%+7.6%$50.32 bn27.9%$46.28 bn27.6%$55.80 bn29.8%$45.23 bn24.8%$42.49 bn24.3%

Debts due in less than a year. At Johnson & Johnson, in 2025: $54.13 bn · Δ +7.6% (2024).

Accounts payable$11.99 bn6.0%+16.3%$10.31 bn5.7%$9.63 bn5.7%$9.89 bn5.3%$11.06 bn6.1%$9.51 bn5.4%
Short-term debt$8.50 bn4.3%+42.0%$5.98 bn3.3%$3.45 bn2.1%$12.76 bn6.8%$3.77 bn2.1%$2.63 bn1.5%
Current portion of long-term debt$8.50 bn4.3%+42.0%$5.98 bn3.3%$3.45 bn2.1%$12.77 bn6.8%$3.77 bn2.1%$2.63 bn1.5%
Deferred revenue—-—-$2.99 bn1.8%—-—-—-
Other current liabilities$33.64 bn16.9%+11.2%$30.26 bn16.8%$30.21 bn18.0%$30.94 bn16.5%$29.29 bn16.1%$28.97 bn16.6%
$63.54 bn31.9%+9.0%$58.29 bn32.4%$52.50 bn31.3%$54.77 bn29.2%$62.77 bn34.5%$69.12 bn39.5%

Debts due beyond one year. At Johnson & Johnson, in 2025: $63.54 bn · Δ +9.0% (2024).

Long-term debt$39.44 bn19.8%+28.7%$30.65 bn17.0%$25.88 bn15.4%$26.89 bn14.3%$29.99 bn16.5%$32.64 bn18.7%
Total long-term debt$39.44 bn19.8%+28.7%$30.65 bn17.0%$25.88 bn15.4%$26.89 bn14.3%$29.99 bn16.5%$32.64 bn18.7%
Other non-current liabilities$9.87 bn5.0%−43.8%$17.55 bn9.7%$13.40 bn8.0%$21.51 bn11.5%$25.30 bn13.9%$29.27 bn16.7%
of which: deferred liabilities—-—-—-$6.37 bn3.4%$7.49 bn4.1%$7.21 bn4.1%
Other liabilities—-—-—-$26.58 bn14.2%$31.78 bn17.5%$35.39 bn20.2%
$81.54 bn40.9%+14.1%$71.49 bn39.7%$68.77 bn41.0%$76.80 bn41.0%$74.02 bn40.7%$63.28 bn36.2%

What would be left for shareholders if everything were sold and every debt paid. At Johnson & Johnson, in 2025: $81.54 bn · Δ +14.1% (2024).

$3.12 bn1.6%$3.12 bn1.7%$3.12 bn1.9%$3.12 bn1.7%$3.12 bn1.7%$3.12 bn1.8%

Money put in by shareholders at founding and at capital raises. At Johnson & Johnson, in 2025: $3.12 bn.

$3.12 bn1.6%$3.12 bn1.7%$3.12 bn1.9%$3.12 bn1.7%$3.12 bn1.7%$3.12 bn1.8%

Capital subscribed by shareholders. At Johnson & Johnson, in 2025: $3.12 bn.

—-—-$00.0%$00.0%$00.0%$00.0%

What shareholders paid above the nominal value of the shares.

$168.98 bn84.8%+8.5%$155.79 bn86.5%$153.84 bn91.8%$128.35 bn68.5%$123.06 bn67.6%$113.89 bn65.1%

Past years’ profits the company kept instead of distributing. At Johnson & Johnson, in 2025: $168.98 bn · Δ +8.5% (2024).

Retained earnings, total—-—-—-$128.35 bn68.5%$123.06 bn67.6%$113.89 bn65.1%
Accumulated other comprehensive income−$14.93 bn-7.5%−27.2%−$11.74 bn-6.5%−$12.53 bn-7.5%−$12.97 bn-6.9%−$13.06 bn-7.2%−$15.24 bn-8.7%
Other equity items−$75.62 bn-38.0%+0.1%−$75.68 bn-42.0%−$75.66 bn-45.2%−$41.69 bn-22.3%−$39.10 bn-21.5%−$38.49 bn-22.0%
—-—-−$75.66 bn-45.2%−$41.69 bn-22.3%−$39.10 bn-21.5%−$38.49 bn-22.0%

Own shares bought back by the company and taken out of circulation.

Common stock, total—-—-—-$3.12 bn1.7%$3.12 bn1.7%$3.12 bn1.8%
Non-controlling interests—-—-$00.0%$00.0%$00.0%$00.0%
$199.21 bn100%+10.6%$180.10 bn100%$167.56 bn100%$187.38 bn100%$182.02 bn100%$174.89 bn100%

Liabilities plus equity. Must equal total assets. At Johnson & Johnson, in 2025: $199.21 bn · Δ +10.6% (2024).

$28.22 bn14.2%+125%$12.53 bn7.0%$7.47 bn4.5%$26.75 bn14.3%$19.26 bn10.6%$21.28 bn12.2%

Debt left after subtracting cash in the bank. Negative means more money than debt. At Johnson & Johnson, in 2025: $28.22 bn · Δ +125% (2024).

$47.93 bn24.1%+30.8%$36.63 bn20.3%$29.33 bn17.5%$39.64 bn21.2%$33.75 bn18.5%$35.27 bn20.2%

All borrowings, short and long term. At Johnson & Johnson, in 2025: $47.93 bn · Δ +30.8% (2024).

$1.50 bn0.8%−73.1%$5.57 bn3.1%$7.21 bn4.3%−$508.0 m-0.3%$15.75 bn8.7%$8.74 bn5.0%

The difference between what it collects and what it pays in the short term. At Johnson & Johnson, in 2025: $1.50 bn · Δ −73.1% (2024).

—-—-—-−$16.75 bn-8.9%−$13.07 bn-7.2%−$26.52 bn-15.2%

Assets without goodwill and licences, that is only what can be touched.

$129.48 bn65.0%+19.7%$108.12 bn60.0%$98.11 bn58.6%$116.46 bn62.2%$107.77 bn59.2%$98.54 bn56.3%

The capital the business actually has at work. At Johnson & Johnson, in 2025: $129.48 bn · Δ +19.7% (2024).

2.43 bn-2.43 bn-2.56 bn-2.66 bn-2.67 bn-2.67 bn-

How many shares exist. If the number rises, each shareholder’s slice shrinks. At Johnson & Johnson, in 2025: $2.43 bn.

total assets$200.89 bn+3.7%Q2 24Q1 26Q2 24$181.09 bnQ3 24$178.29 bnQ4 24$180.10 bnQ1 25$193.67 bnQ2 25$193.39 bnQ3 25$192.82 bnQ4 25$199.21 bnQ1 26$200.89 bn
total liabilities$119.71 bn+3.6%Q2 24Q1 26Q2 24$109.55 bnQ3 24$108.13 bnQ4 24$108.61 bnQ1 25$115.56 bnQ2 25$114.92 bnQ3 25$113.54 bnQ4 25$117.67 bnQ1 26$119.71 bn
shareholders equity$81.19 bn+3.9%Q2 24Q1 26Q2 24$71.54 bnQ3 24$70.16 bnQ4 24$71.49 bnQ1 25$78.11 bnQ2 25$78.47 bnQ3 25$79.28 bnQ4 25$81.54 bnQ1 26$81.19 bn
Balance sheet, quarterly, 6 periods
 Q1 26Δ Q1 25Q4 25Q3 25Q2 25Q1 25Q4 24
$200.89 bn100%+3.7%$199.21 bn100%$192.82 bn100%$193.39 bn100%$193.67 bn100%$180.10 bn100%

Everything the company owns: factories, inventory, cash, receivables. At Johnson & Johnson, in Q1 26: $200.89 bn · Δ +3.7% (Q1 25).

$59.17 bn29.5%−17.3%$55.62 bn27.9%$54.61 bn28.3%$54.50 bn28.2%$71.55 bn36.9%$55.89 bn31.0%

What turns into money in less than a year. At Johnson & Johnson, in Q1 26: $59.17 bn · Δ −17.3% (Q1 25).

Cash$21.69 bn10.8%−43.6%$19.71 bn9.9%$18.23 bn9.5%$18.58 bn9.6%$38.47 bn19.9%$24.11 bn13.4%
Cash and equivalents—-$5.99 bn3.0%$5.30 bn2.7%$4.64 bn2.4%$19.69 bn10.2%$6.12 bn3.4%
Short-term investments$363.0 m0.2%+18.2%$393.0 m0.2%$331.0 m0.2%$303.0 m0.2%$307.0 m0.2%$417.0 m0.2%
Cash and short-term investments$22.05 bn11.0%−43.1%$20.10 bn10.1%$18.56 bn9.6%$18.88 bn9.8%$38.78 bn20.0%$24.52 bn13.6%
Net receivables$17.72 bn8.8%+10.6%$17.18 bn8.6%$17.61 bn9.1%$17.85 bn9.2%$16.02 bn8.3%$18.93 bn10.5%
Inventory$14.58 bn7.3%+15.2%$14.19 bn7.1%$14.15 bn7.3%$13.41 bn6.9%$12.66 bn6.5%$12.44 bn6.9%
Other current assets$4.82 bn2.4%+17.8%$4.15 bn2.1%$4.29 bn2.2%$4.36 bn2.3%$4.09 bn2.1%—-
$141.72 bn70.5%+16.1%$143.59 bn72.1%$138.21 bn71.7%$138.89 bn71.8%$122.12 bn63.1%$124.21 bn69.0%

What stays in the company for years: buildings, machinery, licences. At Johnson & Johnson, in Q1 26: $141.72 bn · Δ +16.1% (Q1 25).

Property, plant and equipment—-$24.47 bn12.3%$22.34 bn11.6%$21.95 bn11.3%$20.87 bn10.8%$21.62 bn12.0%
PP&E, net$54.70 bn27.2%+162%$23.17 bn11.6%$53.38 bn27.7%$21.95 bn11.3%$20.87 bn10.8%$20.52 bn11.4%
$54.70 bn27.2%+9.6%$54.36 bn27.3%$53.38 bn27.7%$52.47 bn27.1%$49.88 bn25.8%$48.77 bn27.1%

The purchase value of buildings and machinery, before accumulated depreciation. That is why it exceeds the net value. At Johnson & Johnson, in Q1 26: $54.70 bn · Δ +9.6% (Q1 25).

Goodwill$48.56 bn24.2%+9.2%$48.77 bn24.5%$48.05 bn24.9%$48.12 bn24.9%$44.47 bn23.0%$44.20 bn24.5%
Intangible assets$49.06 bn24.4%+33.5%$50.40 bn25.3%$48.74 bn25.3%$49.84 bn25.8%$36.76 bn19.0%$37.62 bn20.9%
Other non-current assets−$17.32 bn-8.6%−250%$14.37 bn7.2%−$18.62 bn-9.7%$12.19 bn6.3%$11.53 bn6.0%$11.41 bn6.3%
Other assets—-$19.28 bn9.7%$18.51 bn9.6%$18.54 bn9.6%$19.25 bn9.9%$20.32 bn11.3%
$119.71 bn59.6%+3.6%$117.67 bn59.1%$113.54 bn58.9%$114.92 bn59.4%$115.56 bn59.7%$108.61 bn60.3%

Everything the company owes, to banks and suppliers alike. At Johnson & Johnson, in Q1 26: $119.71 bn · Δ +3.6% (Q1 25).

$57.72 bn28.7%+1.4%$54.13 bn27.2%$50.87 bn26.4%$54.18 bn28.0%$56.90 bn29.4%$50.32 bn27.9%

Debts due in less than a year. At Johnson & Johnson, in Q1 26: $57.72 bn · Δ +1.4% (Q1 25).

Accounts payable$10.46 bn5.2%+9.6%$11.99 bn6.0%$9.63 bn5.0%$9.46 bn4.9%$9.55 bn4.9%$10.31 bn5.7%
Short-term debt$17.46 bn8.7%+25.6%$8.50 bn4.3%$6.39 bn3.3%$11.53 bn6.0%$13.90 bn7.2%$5.98 bn3.3%
Current portion of long-term debt$17.46 bn8.7%+25.6%$8.50 bn4.3%$6.39 bn3.3%$11.53 bn6.0%$13.90 bn7.2%$5.98 bn3.3%
Other current liabilities$28.71 bn14.3%−1.8%$33.64 bn16.9%$32.93 bn17.1%$31.53 bn16.3%$29.24 bn15.1%$30.26 bn16.8%
$61.99 bn30.9%+5.7%$63.54 bn31.9%$62.67 bn32.5%$60.74 bn31.4%$58.66 bn30.3%$58.29 bn32.4%

Debts due beyond one year. At Johnson & Johnson, in Q1 26: $61.99 bn · Δ +5.7% (Q1 25).

Long-term debt$37.53 bn18.7%−2.2%$39.44 bn19.8%$39.41 bn20.4%$39.24 bn20.3%$38.36 bn19.8%$30.65 bn17.0%
Total long-term debt$37.53 bn18.7%−2.2%$39.44 bn19.8%$39.41 bn20.4%$39.24 bn20.3%$38.36 bn19.8%$30.65 bn17.0%
Other non-current liabilities$10.21 bn5.1%−2.2%$9.87 bn5.0%$9.93 bn5.1%$10.26 bn5.3%$10.44 bn5.4%$17.55 bn9.7%
$81.19 bn40.4%+3.9%$81.54 bn40.9%$79.28 bn41.1%$78.47 bn40.6%$78.11 bn40.3%$71.49 bn39.7%

What would be left for shareholders if everything were sold and every debt paid. At Johnson & Johnson, in Q1 26: $81.19 bn · Δ +3.9% (Q1 25).

$3.12 bn1.6%$3.12 bn1.6%$3.12 bn1.6%$3.12 bn1.6%$3.12 bn1.6%$3.12 bn1.7%

Money put in by shareholders at founding and at capital raises. At Johnson & Johnson, in Q1 26: $3.12 bn.

$3.12 bn1.6%$3.12 bn1.6%$3.12 bn1.6%$3.12 bn1.6%$3.12 bn1.6%$3.12 bn1.7%

Capital subscribed by shareholders. At Johnson & Johnson, in Q1 26: $3.12 bn.

$169.16 bn84.2%+4.0%$168.98 bn84.8%$167.28 bn86.8%$165.37 bn85.5%$162.64 bn84.0%$155.79 bn86.5%

Past years’ profits the company kept instead of distributing. At Johnson & Johnson, in Q1 26: $169.16 bn · Δ +4.0% (Q1 25).

Accumulated other comprehensive income−$14.83 bn-7.4%−26.3%−$14.93 bn-7.5%−$15.24 bn-7.9%−$14.31 bn-7.4%−$11.74 bn-6.1%−$11.74 bn-6.5%
Other equity items−$76.26 bn-38.0%−0.5%−$75.62 bn-38.0%−$75.89 bn-39.4%−$75.71 bn-39.2%−$75.91 bn-39.2%−$75.68 bn-42.0%
$200.89 bn100%+3.7%$199.21 bn100%$192.82 bn100%$193.39 bn100%$193.67 bn100%$180.10 bn100%

Liabilities plus equity. Must equal total assets. At Johnson & Johnson, in Q1 26: $200.89 bn · Δ +3.7% (Q1 25).

−$4.23 bn-2.1%−131%$28.22 bn14.2%$27.56 bn14.3%$32.18 bn16.6%$13.78 bn7.1%$12.53 bn7.0%

Debt left after subtracting cash in the bank. Negative means more money than debt. At Johnson & Johnson, in Q1 26: −$4.23 bn · Δ −131% (Q1 25).

$54.99 bn27.4%+5.2%$47.93 bn24.1%$45.80 bn23.8%$50.76 bn26.2%$52.25 bn27.0%$36.63 bn20.3%

All borrowings, short and long term. At Johnson & Johnson, in Q1 26: $54.99 bn · Δ +5.2% (Q1 25).

$1.46 bn0.7%−90.1%$1.50 bn0.8%$3.74 bn1.9%$318.0 m0.2%$14.65 bn7.6%$5.57 bn3.1%

The difference between what it collects and what it pays in the short term. At Johnson & Johnson, in Q1 26: $1.46 bn · Δ −90.1% (Q1 25).

$136.17 bn67.8%+4.5%$129.48 bn65.0%$125.07 bn64.9%$129.23 bn66.8%$130.36 bn67.3%$108.12 bn60.0%

The capital the business actually has at work. At Johnson & Johnson, in Q1 26: $136.17 bn · Δ +4.5% (Q1 25).

2.45 bn-+0.9%2.44 bn-2.43 bn-2.42 bn-2.42 bn-2.43 bn-

How many shares exist. If the number rises, each shareholder’s slice shrinks. At Johnson & Johnson, in Q1 26: $2.45 bn · Δ +0.9% (Q1 25).

from operations$24.53 bn+1.1%201620252016$18.77 bn2017$21.06 bn2018$22.20 bn2019$23.42 bn2020$23.54 bn2021$23.41 bn2022$21.19 bn2023$22.79 bn2024$24.27 bn2025$24.53 bn
from investing−$23.59 bn−26.8%201620252016−$4.76 bn2017−$14.87 bn2018−$3.17 bn2019−$6.19 bn2020−$20.83 bn2021−$8.68 bn2022−$12.37 bn2023$878.0 m2024−$18.60 bn2025−$23.59 bn
from financing−$5.54 bn−76.9%201620252016−$8.55 bn2017−$7.67 bn2018−$18.51 bn2019−$18.02 bn2020−$6.12 bn2021−$14.05 bn2022−$8.87 bn2023−$15.83 bn2024−$3.13 bn2025−$5.54 bn
Cash flows, annual, 6 periods
 2025Δ 202420242023202220212020
$26.80 bn-+90.6%$14.07 bn-$35.15 bn-$17.94 bn-$20.88 bn-$14.71 bn-

The profit left for shareholders after absolutely every expense. At Johnson & Johnson, in 2025: $26.80 bn · Δ +90.6% (2024).

$7.50 bn-+2.2%$7.34 bn-$7.49 bn-$6.97 bn-$7.39 bn-$7.23 bn-

The accounting wear on buildings and machinery. It lowers profit but takes no cash out. At Johnson & Johnson, in 2025: $7.50 bn · Δ +2.2% (2024).

$1.35 bn-+15.1%$1.18 bn-$1.16 bn-$1.14 bn-$1.14 bn-$1.01 bn-

Shares given to employees instead of money. No cash cost, but it dilutes shareholders. At Johnson & Johnson, in 2025: $1.35 bn · Δ +15.1% (2024).

—-—-—-$294.0 m-−$620.0 m-−$1.10 bn-

Adjustments that bring accounting profit closer to money collected.

−$12.72 bn-−792%$1.84 bn-$2.51 bn-−$4.01 bn-−$4.24 bn-$2.69 bn-

Money tied up in or released from inventory, receivables and payables. At Johnson & Johnson, in 2025: −$12.72 bn · Δ −792% (2024).

of which: receivables−$1.78 bn-−339%−$406.0 m-−$624.0 m-−$1.29 bn-−$2.40 bn-$774.0 m-
of which: receivables, total—-—-—-−$1.29 bn-−$2.40 bn-$774.0 m-
of which: inventory−$1.45 bn-−28.5%−$1.13 bn-−$1.32 bn-−$2.53 bn-−$1.25 bn-−$265.0 m-
of which: liabilities—-—-—-−$881.0 m-$1.38 bn-$5.89 bn-
of which: other changes—-—-—-−$1.29 bn-−$3.03 bn-−$2.96 bn-
Other operating flows—-—-—-$687.0 m-−$1.96 bn-−$3.70 bn-
Other non-cash items$49.0 m-−97.6%$2.03 bn-$2.50 bn-$819.0 m-$324.0 m-−$963.0 m-
$24.53 bn-+1.1%$24.27 bn-$22.79 bn-$21.19 bn-$23.41 bn-$23.54 bn-

The money the business actually produced, before investment. At Johnson & Johnson, in 2025: $24.53 bn · Δ +1.1% (2024).

$4.83 bn-+9.2%$4.42 bn-$4.54 bn-$4.01 bn-$3.65 bn-$3.35 bn-

Money put into factories, machinery and equipment. At Johnson & Johnson, in 2025: $4.83 bn · Δ +9.2% (2024).

$741.0 m-+104%−$18.60 bn-$878.0 m-$9.23 bn-−$5.39 bn-−$8.95 bn-

Purchases and sales of financial holdings. At Johnson & Johnson, in 2025: $741.0 m · Δ +104% (2024).

Other investing flows−$1.96 bn-−932%$235.0 m-−$3.06 bn-−$17.59 bn-$357.0 m-−$8.53 bn-
−$23.59 bn-−26.8%−$18.60 bn-$878.0 m-−$12.37 bn-−$8.68 bn-−$20.83 bn-

The balance of investing cash. Negative means the company is building. At Johnson & Johnson, in 2025: −$23.59 bn · Δ −26.8% (2024).

−$5.95 bn-−145%−$2.43 bn-−$5.05 bn-−$6.04 bn-−$3.46 bn-−$3.22 bn-

Shares bought back from the market or issued. At Johnson & Johnson, in 2025: −$5.95 bn · Δ −145% (2024).

$0-$0-$4.24 bn-$0-$0-—-

Money raised by issuing new shares. At Johnson & Johnson, in 2025: $0.

$12.38 bn-+4.7%$11.82 bn-$11.77 bn-$11.68 bn-$11.03 bn-$10.48 bn-

Money given to shareholders as dividends. At Johnson & Johnson, in 2025: $12.38 bn · Δ +4.7% (2024).

$9.64 bn-−4.1%$10.05 bn-−$2.73 bn-$7.45 bn-−$990.0 m-$7.10 bn-

Loans taken minus loans repaid. At Johnson & Johnson, in 2025: $9.64 bn · Δ −4.1% (2024).

Other financing flows$3.16 bn-+195%$1.07 bn-−$508.0 m-$17.53 bn-$395.0 m-−$627.0 m-
−$5.54 bn-−76.9%−$3.13 bn-−$15.83 bn-−$8.87 bn-−$14.05 bn-−$6.12 bn-

The balance of financing cash: loans, dividends, buybacks. At Johnson & Johnson, in 2025: −$5.54 bn · Δ −76.9% (2024).

−$4.40 bn-−296%$2.25 bn-$7.73 bn-−$360.0 m-$502.0 m-−$3.32 bn-

How much the cash in the bank rose or fell. At Johnson & Johnson, in 2025: −$4.40 bn · Δ −296% (2024).

Change in cash and equivalents—-—-—-−$48.0 m-$680.0 m-−$3.41 bn-
$24.11 bn-+10.3%$21.86 bn-$14.13 bn-$14.49 bn-$13.99 bn-$17.31 bn-

Cash in the bank at the start of the period. At Johnson & Johnson, in 2025: $24.11 bn · Δ +10.3% (2024).

$19.71 bn-−18.2%$24.11 bn-$21.86 bn-$14.13 bn-$14.49 bn-$13.99 bn-

Cash in the bank at the end of the period. At Johnson & Johnson, in 2025: $19.71 bn · Δ −18.2% (2024).

$19.70 bn-−0.7%$19.84 bn-$18.25 bn-$17.19 bn-$19.76 bn-$20.19 bn-

The money left after the business paid for its investments. Dividends and debt repayment come from here. At Johnson & Johnson, in 2025: $19.70 bn · Δ −0.7% (2024).

from operations$2.51 bn−39.8%Q2 24Q1 26Q2 24$5.63 bnQ3 24$7.99 bnQ4 24$6.98 bnQ1 25$4.17 bnQ2 25$3.88 bnQ3 25$9.17 bnQ4 25$7.31 bnQ1 26$2.51 bn
from investing−$1.04 bn−250%Q2 24Q1 26Q2 24−$13.69 bnQ3 24−$3.13 bnQ4 24−$1.32 bnQ1 25−$297.0 mQ2 25−$18.26 bnQ3 25−$542.0 mQ4 25−$4.49 bnQ1 26−$1.04 bn
from financing$530.0 m−94.9%Q2 24Q1 26Q2 24$7.54 bnQ3 24−$9.88 bnQ4 24−$1.34 bnQ1 25$10.42 bnQ2 25−$5.67 bnQ3 25−$8.93 bnQ4 25−$1.37 bnQ1 26$530.0 m
Cash flows, quarterly, 6 periods
 Q1 26Δ Q1 25Q4 25Q3 25Q2 25Q1 25Q4 24
$5.24 bn-−52.4%$5.12 bn-$5.15 bn-$5.54 bn-$11.00 bn-$3.43 bn-

The profit left for shareholders after absolutely every expense. At Johnson & Johnson, in Q1 26: $5.24 bn · Δ −52.4% (Q1 25).

$2.00 bn-+13.1%$2.01 bn-$1.78 bn-$1.94 bn-$1.77 bn-$1.90 bn-

The accounting wear on buildings and machinery. It lowers profit but takes no cash out. At Johnson & Johnson, in Q1 26: $2.00 bn · Δ +13.1% (Q1 25).

$300.0 m-+4.2%$309.0 m-$347.0 m-$410.0 m-$288.0 m-$238.0 m-

Shares given to employees instead of money. No cash cost, but it dilutes shareholders. At Johnson & Johnson, in Q1 26: $300.0 m · Δ +4.2% (Q1 25).

−$5.23 bn-+52.6%−$12.72 bn-$15.95 bn-−$4.92 bn-−$11.02 bn-$798.0 m-

Money tied up in or released from inventory, receivables and payables. At Johnson & Johnson, in Q1 26: −$5.23 bn · Δ +52.6% (Q1 25).

of which: receivables−$595.0 m-+35.7%$391.0 m-$111.0 m-−$1.36 bn-−$926.0 m-$853.0 m-
of which: inventory−$431.0 m-−195%−$46.0 m-−$748.0 m-−$510.0 m-−$146.0 m-−$90.0 m-
Other non-cash items$42.0 m-+227%$16.27 bn-−$16.27 bn-$84.0 m-−$33.0 m-$636.0 m-
$2.51 bn-−39.8%$7.31 bn-$9.17 bn-$3.88 bn-$4.17 bn-$6.98 bn-

The money the business actually produced, before investment. At Johnson & Johnson, in Q1 26: $2.51 bn · Δ −39.8% (Q1 25).

$1.05 bn-+29.7%$1.84 bn-$788.0 m-$1.40 bn-$809.0 m-$2.15 bn-

Money put into factories, machinery and equipment. At Johnson & Johnson, in Q1 26: $1.05 bn · Δ +29.7% (Q1 25).

$65.0 m-+122%$2.31 bn-−$542.0 m-−$18.26 bn-−$297.0 m-−$1.32 bn-

Purchases and sales of financial holdings. At Johnson & Johnson, in Q1 26: $65.0 m · Δ +122% (Q1 25).

Other investing flows−$56.0 m-−111%$458.0 m-−$2.31 bn-−$634.0 m-$531.0 m-$265.0 m-
−$1.04 bn-−250%−$4.49 bn-−$542.0 m-−$18.26 bn-−$297.0 m-−$1.32 bn-

The balance of investing cash. Negative means the company is building. At Johnson & Johnson, in Q1 26: −$1.04 bn · Δ −250% (Q1 25).

−$4.03 bn-−89.4%−$1.92 bn-−$1.90 bn-−$1.57 bn-−$2.13 bn-−$282.0 m-

Shares bought back from the market or issued. At Johnson & Johnson, in Q1 26: −$4.03 bn · Δ −89.4% (Q1 25).

—-—-—-—-—-$0-

Money raised by issuing new shares.

$3.13 bn-+4.8%$3.13 bn-$3.13 bn-$3.13 bn-$2.99 bn-$2.98 bn-

Money given to shareholders as dividends. At Johnson & Johnson, in Q1 26: $3.13 bn · Δ +4.8% (Q1 25).

$7.21 bn-−52.1%$2.11 bn-−$5.14 bn-−$2.38 bn-$15.05 bn-$1.54 bn-

Loans taken minus loans repaid. At Johnson & Johnson, in Q1 26: $7.21 bn · Δ −52.1% (Q1 25).

Other financing flows−$697.0 m-−243%−$6.0 m-$5.34 bn-−$267.0 m-$487.0 m-$391.0 m-
$530.0 m-−94.9%−$1.37 bn-−$8.93 bn-−$5.67 bn-$10.42 bn-−$1.34 bn-

The balance of financing cash: loans, dividends, buybacks. At Johnson & Johnson, in Q1 26: $530.0 m · Δ −94.9% (Q1 25).

$1.98 bn-−86.2%$1.48 bn-−$346.0 m-−$19.90 bn-$14.37 bn-$4.13 bn-

How much the cash in the bank rose or fell. At Johnson & Johnson, in Q1 26: $1.98 bn · Δ −86.2% (Q1 25).

$19.71 bn-−18.2%$18.23 bn-$18.58 bn-$38.47 bn-$24.11 bn-$19.98 bn-

Cash in the bank at the start of the period. At Johnson & Johnson, in Q1 26: $19.71 bn · Δ −18.2% (Q1 25).

$21.69 bn-−43.6%$19.71 bn-$18.23 bn-$18.58 bn-$38.47 bn-$24.11 bn-

Cash in the bank at the end of the period. At Johnson & Johnson, in Q1 26: $21.69 bn · Δ −43.6% (Q1 25).

$1.47 bn-−56.5%$5.47 bn-$8.38 bn-$2.48 bn-$3.37 bn-$4.84 bn-

The money left after the business paid for its investments. Dividends and debt repayment come from here. At Johnson & Johnson, in Q1 26: $1.47 bn · Δ −56.5% (Q1 25).

earnings and surprises

88%Beat rate

Beats consistently

Next report

for Q2 26

Not yet announcedThe announced date, 15 July 2026, has passed. The company has not yet given the next one.

Earnings per share expected2.85between 2.65 and 3.00
Revenue expected$25.00 bn15 analysts
Last time+0.8%2.70 against 2.68 expected

What analysts expect from Johnson & Johnson, further out

  • earnings per share estimated, fiscal year 2026 · 25 analysts11.58
  • earnings per share estimated, fiscal year 2027 · 25 analysts12.71

Johnson & Johnson beat history

last 8 quarters

Beat rateBeat rateBeat rateBeat rateBeat rateBeat rateAverage reaction when it missesBeat rate

Of the last 8 quarterly reports from Johnson & Johnson, 7 came in above analyst estimates and 1 below. The average surprise is +3.54%, and the latest was +0.75%, with earnings per share of 2.70 against 2.68 expected.

Beat rate88%surprise trend: slowing
Average reaction when it beats+1.4%of 7 beats, the price rose 4 times
Average reaction when it misses−0.1%

How the Johnson & Johnson share price reacted

The move in Johnson & Johnson shares on the day after each report. The middle line is zero.

reportresultnext day5 days
14 April 2026++0.8%+0.90%5z −5.8%
21 January 2026−0.0%−0.09%5z +4.5%
14 October 2025++1.5%−0.03%5z +0.5%
16 July 2025++3.4%+6.19%5z +2.6%
15 April 2025++7.4%−0.48%5z +1.2%
22 January 2025++1.5%−1.94%5z +4.1%
15 October 2024++9.5%+1.55%5z −0.4%
17 July 2024++4.4%+3.69%5z −0.2%

The pattern shows: of those 7 beats, the price rose 4 times. The market does not react to the result, but to the difference from what was already in the price.

How the price moves around the reportover the last 8 reports
0.0%−2.4%+2.0%−0.1%
15 days beforereport day15 days after
Before the report
  • 5d before+1.6%rose 75% of the time
  • 10d before+1.4%rose 62% of the time
  • 21d before+0.7%rose 50% of the time
  • 42d before+3.3%rose 88% of the time
After the report
  • next day−0.1%rose 62% of the time
  • 5d after+0.8%rose 62% of the time
  • 10d after+1.1%rose 62% of the time
  • 15d after+1.6%rose 62% of the time
60% of the move, before40% at the announcement and after

The move is already in the price Of everything that moves the price around the report, 60% happens before the announcement. By the time the news is public, it is already in the quote.

The pattern repeats in 75% of cases, on a sample of 8 quarters. It remains a small sample.

Everything is measured against the price on the report day, marked by the vertical line. Each half is the average of the trajectories from the quarters with enough price history, which is why the samples can differ.

What can go wrong

Risks & Resilience

Risks in Johnson & Johnson (JNJ) stock: balance sheet strength, distance from financial distress, and behaviour in past crises. The low-risk score is 86.6 out of 100, in the upper end of the market.

86.6 · strongLow risk

debt and solvency

97.2credit health

Nothing to fault

A balance sheet is judged on two things: whether the company can pay its debts out of what it produces, and how far it is from not being able to pay them at all. For Johnson & Johnson, both answers are below.

Can it pay its debts?

Johnson & Johnson: Yes, with room to spare. Operating profit covers interest 41.42 times over, and the debt clears in 1.52 years of operating profit.

7597.2Credit health scoreComposite score summarising the firm's ability to carry its debt. Above 70 points to a solid balance sheet.
351.52xDebt / EBITDAHow many years of operating profit it would take to cover total debt. Below 3 is comfortable; above 4 becomes a burden.
1.5341.42xInterest coverageHow many times operating profit covers the interest the company owes in a year. Above 3 is comfortable; below 1.5 means interest eats almost all the profit.
319.11Distance to default (Merton)How many standard deviations the firm value sits above its debt level. Above 3 is a comfortable margin.

How close is it to default?

Johnson & Johnson: Very far. The composite score is 5.2 out of 100, on a scale where lower is better, and no model signals strain. Altman places it in the safe zone.

Altman Z'' scoreStatistical model estimating bankruptcy risk, adapted for non-financial firms. Above 2.6 is the safe zone; below 1.1 is the distress zone.
Probability of distress (Ohlson)Statistical model estimating the risk of financial distress. Low means a balance sheet under no strain.
Probability of distress (Zmijewski)Alternative model for estimating financial distress risk. Low means limited risk; useful as a cross-check on the Ohlson model.
Probability of default (Merton)Estimated chance the firm cannot service its debt over one year. Below 1% means negligible credit risk.

Forensic signals

8signals

Statistical models that look for patterns associated with aggressive reporting. Johnson & Johnson: one signal to watch.

The quality of reported profit

Beneish M-scoreModel that detects patterns of aggressive accounting. Below −1.78 means no signals of aggressive reporting. A statistical test, not an accusation.
Montier C-score (0–6)Six warning signals about the quality of accounting. 0–1 is clean; 4 or above calls for caution.
Accruals ratio (Sloan)How much of reported profit is accounting only, rather than cash collected. Low or negative means profit is backed by real money.
Cash conversion rateHow much of accounting profit actually turns into cash. Above 100% means profit is more than covered by real money.
Stock-based compensation dilutionHow much of shareholders' stake is diluted by shares granted to employees. Below 2% a year is bearable dilution.
Goodwill shareHow much of the company’s assets are goodwill - the premium paid over book value in acquisitions. Above 30% of assets means a large part of the balance sheet depends on acquisitions working out.
Tax rate deviationHow far the tax actually paid differs from the statutory rate in the company’s country. Close to zero is normal. A large, sustained deviation is worth a look at the notes.

What the model raised

  • Montier C-scoreto watch

These are statistical screening models, not accusations. A signal means “worth a closer look”, not “this is fraud”. The Beneish, Montier, Sloan and Piotroski models are published in the academic literature; the thresholds used are those from the original papers.

A statistical screening signal, not an accusation of fraud.

Transparency · MAR

behaviour in a crisis

Held up better than its sectortwo crises measured

How Johnson & Johnson shares behaved when the market fell. Not a forecast, but what happened in the crises the company has already been through.

How much of the market's fall it takes on

how much of the market's fall reaches the stock

absorbs part of it11%Takes on only 11% of the market's falls

the market 100%the stock 11%
  • Held up wellHow well the company held up through economic contractions, against the rest of its sector.
  • Held up wellA composite score folding behaviour across every crisis measured, on a 0 to 100 scale.

What happened in past crises

how well it held up through the measured crises

87Held up very well

  • COVID-19 crash−27.4%2020 · far more resilient than its sector
  • 2022 bear market−12.7%2022 · far more resilient than its sector
  • Severe recession−13.8%A 2008-style economic contraction, with the market down about 40%
  • Market correction−6.9%A broad market decline of about 20%

Johnson & Johnson: Mixed behaviour in the measured crises: neither fragile nor defensive.

Maximum drawdown is measured from peak to trough, on the actual price of that period. The scenarios are estimates, computed from historical sensitivity to the market.

Johnson & Johnson (JNJ) stock: biggest drops and how long the recovery took

The falls the price has been through, from a peak to the lowest point, and how long it took to recover.

Biggest drops since 2010

From a peak to the lowest point after it, how long the fall lasted and how long the recovery took.

  • Feb 2020 - Mar 2020-27.8%fell for 2 months, then took 31 days to get back to the peak
  • Apr 2022 - Jan 2025-23.6%fell for 2 years and 9 months, then took 9 months to get back to the peak
  • Jan 2018 - May 2018-19.4%fell for 4 months, then took 20 months to get back to the peak

Measured on each day’s closing price, adjusted for splits, since 2010-01-04. Elsewhere on this page, drops are measured with dividends reinvested, which is why they can come out slightly smaller there.

What you get while you wait

Dividends and shareholder return

How much Johnson & Johnson pays in dividends, how secure it is, and what happens to the share count.

dividends

2.03%Trailing yield

Johnson & Johnson pays quarterly and has distributed $5.24 per share over the past twelve months, or 2.03% of today's price. Of its profit, 59.52% goes out as dividend.

How much it pays and how secure it is

Trailing yieldDividends over the past twelve months, divided by today's price.
Forward yieldThe dividend announced for the coming year, divided by today's price.
Payout ratioHow much of profit goes out as dividend. A moderate figure leaves room to grow.
Dividend growth 5YAverage annual growth in dividend per share over five years.
Consecutive years of growthHow many years in a row the dividend per share has grown, without a single break.
Dividend safetyHow well the dividend is covered by profit and by cash.

Recent payments

  • Last dividend$1.34 · ex-date May 26, 2026
  • Frequencyquarterly
  • Payments in the last 12 months5
  • Dividends over 12 months$5.24
  • Cut risk22/100
ex-dateamountvs previous
May 26, 2026$1.34+3.1%
February 24, 2026$1.30+0.0%
November 25, 2025$1.30+0.0%
August 26, 2025$1.30+0.0%
May 27, 2025$1.30+4.8%
February 18, 2025$1.24+0.0%
November 26, 2024$1.24+0.0%
August 27, 2024$1.24—

Past returns do not necessarily repeat.

shareholder return

3.24%total return

Across dividends, buybacks and debt, Johnson & Johnson returned 3.24% of its market value over the past twelve months.

2.18%from dividends
1.64%from buybacks
-0.31%from new debt
3.24%total return
  • 5Y allocation · dividends50.51%
  • 5Y allocation · buybacks19.73%

A negative total return means the company raised capital during the period, through borrowing or new shares, not that it took money from shareholders.

What you would have made

What has already happened, taken out of percentages and put into money.

What you would have made by investing in Johnson & Johnson (JNJ) stock

$1,000 put in Johnson & Johnson stock 10 years ago, with dividends reinvested, would have grown to $2,907, a return of 11.26% a year. On the share price alone, without dividends, it would have been $2,038. Type your own amount and everything recalculates.

$
  • 3 years ago$1,765of which $765 is gain, at 20.84% a year
  • 5 years ago$1,782of which $782 is gain, at 12.25% a year
  • 10 years ago$2,907of which $1,907 is gain, at 11.26% a year

These figures have already happened and are not an estimate for what comes next. Dividends are reinvested in the same stock, and the amounts are in the currency the stock trades in, before tax and fees.

splits

3 events

Johnson & Johnson has had 3 share events over the period covered by the data.

dateratiotype
June 13, 20012:1split
June 12, 19962:1split
June 10, 19922:1split

Amounts in the dividend history are adjusted for these events so they can be compared with each other. The sum actually received on the day was different.

Who owns it and what they do with it

Holders and flow

Who stands behind Johnson & Johnson shares, what they buy and sell, and who bets against them.

institutional ownership

Johnson & Johnson has 76.84% of its shares held by institutional investors. Of the 40 reported holders, 23 increased their position and 15 cut it.

Who holds how much

InstitutionsHow much of the stock is held by funds, banks and other professional investors.
Internal holdingsHow much is held by people and entities inside the company or close to it.
Largest holderHow much the single largest reported shareholder owns.
Top fiveHow much the five largest reported shareholders own together.
  • Reported holders40
  • Increased position23
  • Cut position15
  • Net share balance27.98M
  • As ofApril 30, 2026

Largest holders

Largest holders
holderstakechangeAs of
Vanguard Group Incpassive9.98%+1.58%12/31/2025
BlackRock Incpassive8.67%+0.73%12/31/2025
State Street Corppassive5.54%−0.29%03/31/2026
Vanguard Total Stock Mkt Idx Invpassive3.19%+0.31%04/30/2026
JPMorgan Chase & Coactive2.62%+7.75%03/31/2026
Vanguard 500 Index Investor2.60%+1.83%04/30/2026
Geode Capital Management, LLC2.46%+2.09%03/31/2026
Morgan Stanley - Brokerage Accounts1.86%−3.46%03/31/2026
NORGES BANK1.39%+4.79%12/31/2025
State Farm Mutual Automobile Ins Co1.31%+0.00%03/31/2026
iShares Core S&P 500 ETF1.29%+0.29%04/30/2026
Fidelity 500 Index1.28%+0.37%03/31/2026
Northern Trust Corp1.22%+0.13%03/31/2026
State Street® SPDR® S&P 500® ETF1.20%+0.33%04/30/2026
Bank of America Corp1.18%−0.30%12/31/2025
FMR Inc1.03%+31.93%03/31/2026
Vanguard Value Index Inv0.93%+0.29%04/30/2026
Bank of New York Mellon Corp0.91%−10.54%03/31/2026
Wellington Management Company LLP0.83%−13.61%03/31/2026
UBS Asset Mgmt Americas Inc0.82%+13.62%03/31/2026
Legal & General Group PLC0.80%+3.22%03/31/2026
Charles Schwab Investment Management Inc0.80%+0.75%03/31/2026
The Goldman Sachs Group Inc0.75%+10.51%03/31/2026
State Street®HlthCrSelSectSPDR®ETF0.72%−0.98%04/30/2026
Wells Fargo & Co0.70%−5.15%03/31/2026
T. Rowe Price Associates, Inc.0.69%+32.74%03/31/2026
Dimensional Fund Advisors, Inc.0.66%−8.24%03/31/2026
Vanguard Dividend Appreciation ETF0.56%+0.28%04/30/2026
Vanguard Institutional Index I0.55%−1.75%04/30/2026
State St S&P 500® Idx SL Cl I0.54%+0.99%04/30/2026
Vanguard Institutional 500 Index Trust0.45%−0.08%04/30/2026
Equity Index Fund A0.40%−1.12%12/31/2025
Equity Index Non-Lendable Fund B0.40%+0.00%12/31/2025
Equity Index Fund E0.40%−1.12%12/31/2025
JPMorgan Large Cap Growth I0.39%+0.00%03/31/2026
Vanguard High Dividend Yield ETF0.39%+0.65%04/30/2026
Blackrock Eq Idx Fund CF0.36%−0.35%03/31/2026
Russell 1000 Index Fund0.32%−0.49%04/30/2026
Columbia Dividend Value0.32%−1.94%03/31/2026
Blackrock Russ 1000 Eq Idx Composite0.31%+0.50%12/31/2025
See all holders

The list covers only the largest reported holders, not the whole shareholder base. Stakes do not add up to 100%.

The holder type is noted only where the source states it.

insiders

What they did over the last six months

  • Distinct buyers, 12 months0
  • Distinct sellers, 12 months2
  • Value sold, 12 months$7.36M
  • Cluster buyingno
  • As of02/20/2026

Largest transactions

datenamesidevalue
02/18/2026Timothy Schmidsell$5.53M
02/17/2026Vanessa Broadhurstsell$1.51M
02/20/2026Timothy Schmidsell$324.76K

The source does not state each person's role, so a chief executive and a board member appear the same.

Informational data on reported transactions; not a recommendation.

congress

Over the past twelve months, members of the US Congress reported 7 purchases and 10 sales of Johnson & Johnson shares.

What lawmakers traded

7purchases, 12 months10sales, 12 months
distinct buying members4
  • Purchases, 6 months0
  • Sales, 6 months0
  • Distinct selling members, 12 months6
  • As of03/26/2026

Who traded

Who traded
datenameside
03/26/2026Thomas H. Kean, Jr.sell
03/19/2026John Boozmansell
03/19/2026Richard McCormicksell
03/10/2026Lloyd Doggettbuy
03/06/2026Ro Khannasell
02/05/2026Ro Khannabuy
01/23/2026Thomas H. Kean, Jr.sell
12/18/2025Julie Johnsonsell
12/09/2025Lloyd Doggettbuy
11/20/2025Thomas H. Kean, Jr.sell
11/13/2025Julie Johnsonsell
11/07/2025Ro Khannabuy
11/05/2025Richard McCormickbuy
10/31/2025Lisa C. McClainsell
10/30/2025Lisa C. McClainsell
10/30/2025Lisa C. McClainbuy
10/30/2025Ro Khannabuy
See all transactions

The law requires reporting a value range, not the exact sum. That is why transactions are counted here rather than added up.

Transactions reported under the STOCK Act; informational.

short interest

Of Johnson & Johnson freely tradable shares, 0.01% are sold short.

How much is sold short

Of free floatHow much of the freely tradable stock is sold short.
Days to coverHow many normal trading days it would take for short positions to be closed.
Shares shortThe number of shares sold short at the latest report.
  • Of total shares0.01%
  • Squeeze riskLow
  • As of05/27/2026

Short positions are reported twice a month, so the figure is older than the price on this page.

indices and ETFs

Johnson & Johnson shares are held by 13 exchange-traded funds and belong to 2 indices.

Funds that hold it

Funds that hold it
fundsymbolweightassets
Health Care Select Sector SPDRXLV.US10.30%$39.24B
SPDR Dow Jones Industrial Average ETFDIA.US2.88%$44.9B
Vanguard High Dividend Yield ETFVYM.US2.30%$78.33B
Vanguard Value ETFVTV.US2.16%$179.59B
Vanguard FTSE All-World High Div Yield UCITSVHYL.LSE1.34%$5.61B
SPDR S&P 500 ETF TrustSPY.US90.47%$769.06B
iShares Core S&P 500 UCITSCSPX.LSE90.42%$146.69B
Vanguard S&P 500 ETFVOO.US90.00%$1.03T
Vanguard S&P 500 UCITSVUSA.LSE89.91%$42.99B
Vanguard Total Stock Market Index Fund ETF SharesVTI.US80.00%$653.54B
iShares Core MSCI World UCITSIWDA.LSE65.34%$101.7B
Vanguard FTSE Developed World UCITSVEVE.LSE61.50%$3.44B
Vanguard Total World Stock ETFVT.US49.00%$74.09B
See all funds

Indices it belongs to

  • Dow Jones Industrial Average2.90%
  • S&P 5000.91%

The weight is how much the share counts inside that fund, not how much of the company the fund owns.

Where it stands against the rest

Context & Comparisons

A number on its own says nothing. Here Johnson & Johnson is placed next to its sector, its industry and the market, so every figure gets a position.

Position in sector

Healthcaresector

Johnson & Johnson belongs to the Healthcare sector, in the Drug Manufacturers - General industry. Below, each indicator sits next to the sector and industry median.

Against sector and industry

indicatorcompanysector medianindustry medianposition
27.50%10.50%21.94%84
Return on equityHow much net profit the company generates from shareholders' money. Above ~15% is very good; consistency matters as much as the level.
11.09%4.44%9.21%79
Return on assetsHow much profit the company draws from the assets it owns. Above ~5% is solid, though it varies widely by industry.
21.32%8.66%17.72%87
Return on invested capitalProfit generated from all capital employed — equity and debt alike. Above the cost of capital (WACC) means value is created. Above 15% is very good.
21.83%8.18%17.70%87
Net margin (DuPont breakdown)The margin component of the DuPont breakdown of returns. Higher means the firm keeps more of every unit sold.
27.29x19.54x19.15x32
Price / earnings (trailing 12 months)How many years of current profit you pay for one share. Judged against sector and growth rate, never in isolation.
5.96x2.10x2.25x-
Price / sales (trailing 12 months)How many times annual sales you pay for a share. Useful for companies without profit; judged against the sector, not in absolute terms.
2.20%2.23%3.08%47
Dividend yield (trailing 12 months)Dividends paid over the past year against the current price. Judged together with sustainability, not on level alone.
59.52%33.17%50.71%-
Payout ratioHow much of the profit is paid out as dividend. Below 60% leaves room to grow; above 100% means the dividend exceeds the profit.
2.67%9.21%6.00%19
Revenue growth (5-year annual)Average yearly revenue growth over the past five years. Above ~10% is solid growth for a mature company.
14.90%6.66%15.01%67
Earnings per share growth (5-year annual)Average yearly growth in earnings per share. Faster than revenue means expanding margins or buybacks.
1.52x1.46x1.49x47
Debt / EBITDAHow many years of operating profit it would take to cover total debt. Below 3 is comfortable; above 4 becomes a burden.
3.10%4.77%6.56%46
Free cash flow yieldHow much free cash the company produces relative to its market value. Above ~5% is attractive; below 2% is expensive.

Position is the percentile within the sector: 100 is the best value among the companies compared, 0 the weakest. The direction is already inverted where lower is better, as with debt or price/earnings.

Against the market

periodJNJSPYdifference
1M4.37%-0.08%+4.45%
3M-3.49%12.30%−15.79%
6M16.19%8.49%+7.70%
1Y59.18%24.76%+34.42%
3Y66.18%80.71%−14.53%
5Y60.97%88.11%−27.14%

Returns are cumulative over the period shown, not annualised. The difference is how much the company returned above or below the benchmark.

Transparency · MAR

Comparable companies

6comparable

Companies with a profile close to Johnson & Johnson, chosen by how they move and what kind of stock they are - not by what they make.

The 6 closest

symbolcompanysimilarityscore
MRK.USMerck & Company IncHealthcare84.8%57.0
MCD.USMcDonald’s CorporationConsumer Cyclical83.8%46.9
NVS.USNovartis AG ADRHealthcare82.7%53.6
ABBV.USAbbVie IncHealthcare81.8%39.5
XOM.USExxon Mobil CorpEnergy80.1%48.2
RHHBY.USRoche Holding Ltd ADRHealthcare80.1%54.7

Similarity is computed from exposure to the same style factors, not from the line of business. That is why companies from other sectors can appear in the list. It is not a recommendation and not a list of alternatives.

Direct competitors

symbolcompanycountryscore
ABBV.USAbbVie IncUS39.5
NOVO-B.CONovo Nordisk A/SDK35.5
LLY.USEli Lilly and CompanyUS64.3
MRK.USMerck & Company IncUS57.0
NVS.USNovartis AG ADRUS53.6
RHHBY.USRoche Holding Ltd ADRUS54.7

Competitors from the same industry, Drug Manufacturers - General. The list is ordered by company size, but the figure is not shown: it comes in each market’s own currency, so the values are not comparable.

How the price moves

Market & Momentum

So far this has been about the company. From here on it is about the share: how much it swings, how deep it fell, and whether the move was worth the risk.

Volatility and risk

16.57%one-year volatility

How choppy Johnson & Johnson has been, and how deep its falls have gone.

How much it swings

0.46calmer than the marketBetaHow strongly the share moves when the market moves. Below 1 is calmer than the market; above 1 amplifies its moves.
0.22Downside betaHow much the share moves against the market, measured ONLY on days the market falls. Lower than ordinary beta = falls less than it rises. Higher = amplifies the falls.
0.04Beta over the last yearThe same market sensitivity, but computed on the last twelve months only. Compared with long-term beta, it shows whether the share has turned choppier lately.
0.20Raw betaHow much the share moves against the market, without the usual statistical adjustment. Above 1 = moves more than the market. This is the unsmoothed figure; adjusted beta is steadier.
market
Annualised volatility (1 year)How much the price swings over a year, as a standard deviation. Lower means a smoother ride, not necessarily a higher return.
Annualised volatility (3 years)How widely the price swings in a year, measured over the last three. Below 20% is calm; above 40% takes a strong stomach.

How deep it fell

−27.37%Maximum drawdownThe largest peak-to-trough fall over the period analysed. Smaller is easier to sit through.
−3.49%Current drawdownHow far today’s price sits below the highest peak reached. Zero means it is at the peak. The deeper it is, the more there is to recover.
−4.05%Distance from the 52-week highHow far the price sits below its highest level of the past 52 weeks. Near zero = at the high. Deeply negative = it has given up a lot from the peak.
14.07%Likely worst-case drawdownHow deep the fall could be in the worst 5% of scenarios. Lower is better. It is a statistical estimate, not a guaranteed floor.
Ulcer index (1 year)How deep and how long the falls of the past year were, in a single figure. Lower is better: it measures discomfort, not just swing.
Ulcer index (3 years)How deep and how long the falls below previous peaks have been. Low means few long stretches spent below the peak.
Days to recoverHow many days the price needed to return to its peak after the largest fall. Fewer is better. Hundreds of days means patience was tested.

Volatility and beta are computed from daily prices over the last year and the last three. They measure the past; they are not forecasts.

The words next to the figures are states with established names, not recommendations: “oversold” does not mean “worth buying”. Verdicts appear only on the risk ratios, where there is a clear direction of better.

Return against risk

2.57one-year Sharpe

The same gain earned with wide or narrow swings is not worth the same. The figures below divide the return by the risk it was earned with.

How much return for each unit of risk

2.570.76goodSharpe ratioReturn above the risk-free rate for each unit of volatility. Above 1 is good; above 2 is remarkable.
4.521.12goodSortino ratioLike Sharpe, but only penalising downward swings, not upward ones. Above 1.5 means good return relative to downside risk.
1.551.14goodOmega ratioThe ratio of gains to losses over the past year, weighted by their size. Above 1 means the good side weighed more than the bad.
0
Total return, 12 monthsGain over the past year, with dividends reinvested. Compared with the benchmark index, not in isolation.
Calmar ratioAnnual return divided by the largest drawdown suffered. Above 0.5 is decent. It says how much return you got for each unit of pain.
Treynor ratio (1 year)Return above the risk-free rate divided by beta - against market risk, not total swing. Higher is better. Useful when the share is held in a portfolio rather than alone.

All of them measure gain against some form of risk: Sharpe against total swing, Sortino against downward swing only, Calmar against the deepest fall, Treynor against market risk. Above 1 is generally good, but these compare between companies, not in absolute terms.

The words next to the figures are states with established names, not recommendations: “oversold” does not mean “worth buying”. Verdicts appear only on the risk ratios, where there is a clear direction of better.

Trend and oscillators

64.8414-day RSI

Where the Johnson & Johnson share price sits against its moving averages, and how stretched the recent move is.

Against the averages

50-day moving averageThe average price over the last fifty trading sessions. It is the short-term reference: price above it means a recent upward trend.
200-day moving averageThe average price over the last two hundred sessions. It is the long-term reference, the most watched line in technical analysis.
yesAbove the 200-day averageWhether today’s price is above or below the long-term average. Above is read as a structural uptrend; below, a downtrend.
yesShort average above the long oneWhether the 50-day average is above the 200-day. When the short crosses above the long it is called a golden cross; the reverse, a death cross.
upMoving-average crossover stateWhich average is on top, expressed as +1 or −1. +1 = short above long; −1 = the reverse.
upParabolic SAR directionThe direction signal given by the Parabolic SAR indicator. +1 = uptrend; −1 = downtrend.

Oscillators

307064.84no signalRelative strength index (RSI 14)How fast the price rose or fell over the last fourteen days, on a scale from 0 to 100. Below 30 is considered oversold, above 70 overbought. In between, no signal.
-100100186.72above the channelCommodity channel index (CCI 20)How far the price is from its twenty-day average, measured in typical deviations. Between −100 and +100 is normal; outside that, an unusual move against the recent pattern.
011.01above the bandPosition in the Bollinger bandWhere the price sits between the lower band (0) and the upper band (1) of the volatility channel. Below 0 or above 1 means the price has left the channel - rare, and usually brief.
202513.92no trendTrend strength (ADX 14)How clear the price direction is, whether it rises or falls. Above 25 = a clear trend; below 20 = it moves sideways.
MACD lineThe gap between the 12-day and the 26-day exponential average - how fast direction is changing. Above the signal and rising means upward momentum.
MACD signalThe nine-day average of the MACD line. It is the threshold the line is read against. It is not judged on its own: what matters is whether the line is above or below it.
MACD histogramThe gap between the MACD line and its signal - how fast momentum is changing. Positive and rising = upward momentum; negative = downward momentum.
On-balance volume slope (50 days)Where cumulative volume is heading over the last fifty sessions. Positive means more is being accumulated than distributed.

The thresholds marked on the scales are the usual ones in technical analysis: 30 and 70 for RSI, ±100 for CCI, 0 and 1 for the Bollinger band, 20 and 25 for trend strength. They are widely used conventions, not rules.

The words next to the figures are states with established names, not recommendations: “oversold” does not mean “worth buying”. Verdicts appear only on the risk ratios, where there is a clear direction of better.

Who it suits

19/30checks passed

Each row below is a way of investing. The more checks Johnson & Johnson passes on one, the better it suits that way - there is no “correct” row.

StrongestQuality
WeakestValue
  • passedUpside to fair valueHow much room there is between today’s price and the value computed from discounted cash flows. Positive means the model sees the share below its value.
  • failedPrice / earnings (trailing 12 months)How many years of current profit you pay for one share. Judged against sector and growth rate, never in isolation.
  • failedPrice / sales (trailing 12 months)How many times annual sales you pay for a share. Useful for companies without profit; judged against the sector, not in absolute terms.
  • failedFree cash flow yieldHow much free cash the company produces relative to its market value. Above ~5% is attractive; below 2% is expensive.
  • failedMargin of safetyHow far the market price sits below our fair-value estimate. Positive and wide means buying below value. Negative means paying above it.
  • passedReturn on capital above its costWhether the return on invested capital exceeds the weighted average cost of capital. Above the cost of capital the company creates value; below, it destroys it.
  • passedReturn on equityHow much net profit the company generates from shareholders' money. Above ~15% is very good; consistency matters as much as the level.
  • passedNet margin (DuPont breakdown)The margin component of the DuPont breakdown of returns. Higher means the firm keeps more of every unit sold.
  • passedCompetitive moatHow well defended the company’s position is against competitors. A wide moat means profit is harder to erode.
  • failedPiotroski F-scoreNine balance-sheet and profitability checks, one point for each one passed. Above 7 out of 9 is considered solid; below 3, weak.
  • passedSloan ratioHow much of the profit comes from accounting accruals rather than cash received. Near zero is better: the profit shows up in the account, not just the report.
  • passedWarning flagsThe number of forensic flags raised by the reporting-quality models. Zero is what you want to see.
  • failedDebt / EBITDAHow many years of operating profit it would take to cover total debt. Below 3 is comfortable; above 4 becomes a burden.
  • passedAltman Z'' scoreStatistical model estimating bankruptcy risk, adapted for non-financial firms. Above 2.6 is the safe zone; below 1.1 is the distress zone.
  • passedInterest coverageHow many times operating profit covers the interest the company owes in a year. Above 3 is comfortable; below 1.5 means interest eats almost all the profit.
  • passedProbability of default (Merton)Estimated chance the firm cannot service its debt over one year. Below 1% means negligible credit risk.
  • passedBehaviour in recessionHow the share behaved through recent economic contractions. A smaller fall than the market shows resilience.
  • passedEarnings per share growth (5-year annual)Average yearly growth in earnings per share. Faster than revenue means expanding margins or buybacks.
  • failedRevenue growth (5-year annual)Average yearly revenue growth over the past five years. Above ~10% is solid growth for a mature company.
  • failedRule of 40Revenue growth added to the profitability margin. Above 40 means a good balance between growth and profitability.
  • passedAnalyst revisionsWhich way analysts have moved their estimates lately. Upward means expectations are rising.
  • failedDividend yield (trailing 12 months)Dividends paid over the past year against the current price. Judged together with sustainability, not on level alone.
  • passedPayout ratioHow much of the profit is paid out as dividend. Below 60% leaves room to grow; above 100% means the dividend exceeds the profit.
  • passedStreak of good reportsHow many quarters in a row the company has beaten expectations. A long streak shows predictability; a broken one, a change.
  • passedTotal shareholder yieldDividends, buybacks and debt reduction taken together. The full picture of money returned to shareholders.
  • passedBeats, last yearHow many times over the last year the result came in above estimates. More beats suggest cautious estimates or good execution.
  • failedBeats, three yearsHow many times over the last three years the result came in above estimates. More beats suggest cautious estimates or good execution.
  • failedBeats, five yearsHow many times over the last five years the result came in above estimates. More beats suggest cautious estimates or good execution.
  • passedPrice momentumThe direction and strength of the recent price move. Positive means the recent trend is upward.
  • passedSharpe ratio (1 year)Return above the risk-free rate for each unit of volatility. Above 1 is good; above 2 is remarkable.

A failed check is not a flaw in itself: a growth company fails almost everything to do with value, and that is normal. What matters is the pattern, where it passes and where it fails, not the count on its own.

Transparency · MAR

Key figuresIndicatorsPros and consVerdict
AnalystsFair valueProjections
ProfitabilityGrowthEarnings qualityCapital efficiencyFinancial statementsEarnings reports
Debt and solvencyForensics and manipulationBehaviour in crisesBiggest drops
DividendsShareholder yieldWhat you would have madeSplits
Institutional holdingsInsidersCongressShort interestIndices and ETFs
Position in sectorComparable companiesWho it suits
Volatility and riskRisk-adjusted returnTrend and oscillators